F. Fülöp

Publications702
h-index45
Citations11,159
Highly Influential Citations107
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • F. Fülöp
  • 380 Publications, 1,935 Citations
  • L. Vécsei
  • 489 Publications, 9,249 Citations
  • E. Forró
  • 155 Publications, 2,002 Citations
  • S. Gellman
  • 503 Publications, 25,827 Citations
  • Publications
  • Influence
Kynurenines in the CNS: recent advances and new questions
Various pathologies of the central nervous system (CNS) are accompanied by alterations in tryptophan metabolism. The main metabolic route of tryptophan degradation is the kynurenine pathway; its… Expand
  • 362
  • 17
Effects of SEA0400 and KB-R7943 on Na+/Ca2+ exchange current and L-type Ca2+ current in canine ventricular cardiomyocytes
SEA0400 and KB-R7943 are compounds synthesised to block transsarcolemmal Na+/Ca2+ exchange current (INa/Ca); however, they Have also been shown to inhibit L-type Ca2+ current (ICa). The potential… Expand
  • 112
  • 9
Changing the Face of Kynurenines and Neurotoxicity: Therapeutic Considerations
Kynurenines are the products of tryptophan metabolism. Among them, kynurenine and kynurenic acid are generally thought to have neuroprotective properties, while 3-hydroxykynurenine,… Expand
  • 46
  • 5
  • PDF
Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: Novel therapeutic strategies for neurodegenerative disorders
A mitochondrial dysfunction causes an abatement in ATP production, the induction of oxidative damage and the propagation of cell death pathways. It is additionally closely related to both glutamate… Expand
  • 64
  • 4
Classic preconditioning decreases the harmful accumulation of nitric oxide during ischemia and reperfusion in rat hearts.
BACKGROUND The role of NO in the mechanism of preconditioning is not understood. Therefore, we studied the effect of preconditioning and subsequent ischemia/reperfusion on myocardial NO content in… Expand
  • 139
  • 3
  • PDF
Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies
Parkinson’s, Alzheimer’s and Huntington’s diseases are chronic neurodegenerative disorders of a progressive nature which lead to a considerable deterioration of the quality of life. Their… Expand
  • 74
  • 3
  • PDF
Liquid chromatographic enantioseparation of beta-blocking agents with (1R,2R)-1,3-diacetoxy-1-(4-nitrophenyl)-2-propyl isothiocyanate as chiral derivatizing agent.
The applicability of (1R,2R)-1,3-diacetoxy-1-(4-nitrophenyl)-2-propyl isothiocyanate [(R,R)-DANI] as a recently developed chiral derivatizing agent for the enantioseparation of a series of… Expand
  • 27
  • 3
Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington’s disease
Huntington’s disease (HD) is a progressive neurodegenerative disorder, the pathomechanism of which is not yet fully understood. Excitotoxicity is known to be involved in the development of HD and… Expand
  • 77
  • 2
Neuroprotection with a new kynurenic acid analog in the four-vessel occlusion model of ischemia.
Global forebrain ischemia results in damage to the pyramids in the CA1 hippocampal subfield, which is particularly vulnerable to excitotoxic processes. Morphological and functional disintegration of… Expand
  • 45
  • 2
Electrophysiological effects of ivabradine in dog and human cardiac preparations: potential antiarrhythmic actions.
Ivabradine is a novel antianginal agent which inhibits the pacemaker current. The effects of ivabradine on maximum rate of depolarization (V(max)), repolarization and spontaneous depolarization have… Expand
  • 36
  • 2